ClinicalTrials.gov
public full text
Public Domain
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC#1231274
- A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors#1140863
- Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies#1312093
- Identification of PAthways of Kinase Inhibitors TOxicity#1010715
- Why Do Cancer Patients Decide to Withdraw Their Treatment? A Systematic Review and Meta-Synthesis.#1039851
Record · ID 1353047
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive